Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 3;12(9):2000.
doi: 10.3390/biomedicines12092000.

Glaucoma: Current and New Therapeutic Approaches

Hsin-Pei Lee  1 , Ta-Hsin Tsung  1 , Yu-Chien Tsai  1   2 , Yi-Hao Chen  1 , Da-Wen Lu  1
Affiliations
Review

Glaucoma: Current and New Therapeutic Approaches

Hsin-Pei Lee et al. Biomedicines. .

Abstract

Glaucoma is identified by the loss of retinal ganglion cells (RGCs). The primary approach to managing glaucoma is to control intraocular pressure (IOP). Lately, there has been an increasing focus on neuroprotective therapies for glaucoma because of the limited effectiveness of standard methods in reducing IOP and preventing ongoing vision deterioration in certain glaucoma patients. Various drug-based techniques with neuroprotective properties have demonstrated the ability to decrease the mortality of retinal ganglion cells. This study will analyze the currently recommended drug-based techniques for neuroprotection in the prospective treatment of glaucoma.

Keywords: excitotoxicity; glaucoma therapeutic approaches; neurodegeneration; neuroinflammation; neuroprotection; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Weinreb R.N., Aung T., Medeiros F.A. The pathophysiology and treatment of glaucoma: A review. JAMA. 2014;311:1901–1911. doi: 10.1001/jama.2014.3192. - DOI - PMC - PubMed
    1. Mohan N., Chakrabarti A., Nazm N., Mehta R., Edward D.P. Newer advances in medical management of glaucoma. Indian J. Ophthalmol. 2022;70:1920–1930. doi: 10.4103/ijo.IJO_2239_21. - DOI - PMC - PubMed
    1. Casson R.J., Chidlow G., Ebneter A., Wood J.P., Crowston J., Goldberg I. Translational neuroprotection research in glaucoma: A review of definitions and principles. Clin. Exp. Ophthalmol. 2012;40:350–357. doi: 10.1111/j.1442-9071.2011.02563.x. - DOI - PubMed
    1. Chang E.E., Goldberg J.L. Glaucoma 2.0: Neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology. 2012;119:979–986. doi: 10.1016/j.ophtha.2011.11.003. - DOI - PMC - PubMed
    1. Frishman W.H. A Historical Perspective on the Development of β-Adrenergic Blockers. J. Clin. Hypertens. 2007;9((Suppl. S4)):19–27. doi: 10.1111/j.1524-6175.2007.06633.x. - DOI

LinkOut - more resources